XenoPort, Inc. (NASDAQ:XNPT)
| CAPS Rating |
|
|---|---|
| Open | $4.51 |
| Previous Close | $4.56 |
| Daily Range | $4.29 - $4.57 |
| 52-Week Range | $3.46 - $11.34 |
| Market Cap | $152.39M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 122,305 |
| Average Daily Volume | 0 |
XNPT
VS S&P 500 (SPY)
How do you think XNPT will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
XNPT Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
XNPT News and Commentary
- The Fastest Growers in Pharma – The Motley Fool
- 3 Stocks Stopping the Presses – The Motley Fool
- 5 of Last Week's Biggest Losers – The Motley Fool
- Quest for Alpha: Micro-Cap Stocks With Big Hedge Fund Buying – The Motley Fool
- Aeterna Zentaris Surprises Again – The Motley Fool
- The 20 Fastest Growers in Pharma – The Motley Fool
- Wall Street's Buy List – The Motley Fool
- Xenoport: Favorable Risk/Reward Ratio – SeekingAlpha
- 3 Stocks Stopping the Presses – The Motley Fool
- 10 Small Caps to Rule Them All – The Motley Fool
- 5 of Last Week's Biggest Winners – The Motley Fool
- Top 15 Most Undervalued Biotech Stocks By Analyst Target Price – SeekingAlpha
- Whoa! What Just Happened to My Stock? – The Motley Fool
- Time to Consider Xenoport Among Biotech Strategies for Your Portfolio – SeekingAlpha
- XenoPort: Waiting for the Post-Approval Dust to Settle – SeekingAlpha
- Restless No Longer – The Motley Fool
- FDA approval Biotech News. – Blog at The Motley Fool
- Shares of XenoPort Soar on Drug Approval – Fox Business
- Biotech Catalysts for Q2 2011 – SeekingAlpha
- FDA Approves XenoPort, Glaxo Drug For Restless Leg Syndrome – SmartMoney
RSS Headlines
Fool UK
